# Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

> **NCT01555008** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Renal Impairment

## Interventions

- **DRUG:** LX4211
- **DRUG:** LX4211 Placebo

## Key facts

- **NCT ID:** NCT01555008
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555008, "Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01555008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*